Long-term results of intravitreal ranibizumab, dekzametazon implant and triamcinolone treatment for macular edema due to branch retinal vein occlusion

YÖK Tez ID: 503055Amaç: Retina ven dal tıkanıklığı (RVDT)?na bağlı makula ödeminin tedavisinde intravitreal Ranibizumab, Dekzametazon İmplant ve Triamsinolon (İVTA) enjeksiyonu uygulamalarının uzun dönem etkinlik ve güvenilirliğini karşılaştırmaktır. Gereç ve Yöntem: RVDT?ye bağlı makula ödemi gelişen ve intravitreal enjeksiyon uygulanan 43 hastanın 43 gözü retrospektif olarak incelendi. İntravitreal Ranibizumab (Lucentis®) uygulanan 17, intravitreal Dekzametazon İmplant (Ozurdex®) uygulanan 16 ve İVTA uygulanan 10 hasta çalışmaya alındı. Her üç grup hastada enjeksiyon öncesinde ve sonrası 1. ay, 3. ay, 6. ay ve 12. ayda en iyi düzeltilmiş görme keskinliği (EİDGK), merkezi makula kalınlığı (MMK), subfoveal koroid kalınlığı (SFKK), göz içi basıncı (GİB) ve lens durumu değerlerindeki değişimler incelendi. Bulgular: Hastalar en az bir yıl süresince izlendi. Başlangıç verilerine göre Ranibizumab ve Dekzametazon İmplant grubunda her vizitte; İVTA grubunda ise 1. ve 6. aylarda EİDGK?de anlamlı artış bulundu. MMK her üç grupta da anlamlı olarak azaldı (p=0,007; p=0,001; p=0,044). Ranibizumab grubunda GİB artışı görülmezken; Dekzametazon İmplant grubunda 3 hastada (% 18,8), İVTA grubunda 3 hastada (% 30) GİB artışı görüldü. Ranibizumab grubunda katarakt cerrahisi gerekmezken; Dekzametazon İmplant grubunda 1 hastada (% 6,3) ve İVTA grubunda 3 hastada (% 30) katarakt cerrahisi gerekti. Her üç grupta da SFKK ilk ay anlamlı olarak azalırken diğer aylarda anlamlı değişiklik görülmedi. Sonuç: RVDT?ye bağlı makula ödemi tedavisinde intravitreal Ranibizumab, Dekzametazon İmplant ve Triamsinolon etkili olarak kullanılabilir. Ancak; en güvenilir tedavinin intravitreal Ranibizumab uygulaması ile olduğu söylenebilir. Anahtar Kelimeler: Retina Ven Dal Tıkanıklığı, Makula Ödemi, İntravitreal Ranibizumab, İntravitreal Dekzametazon İmplant, İntravitreal Triamsinolon Asetonid.Purpose:The aim of this study is to evaluate and compare the long-term efficacy and safety of intravitreal Ranibizumab,Dexamethasone Implant and Triamsinolone(IVTA)injections in patients with macular edema due to branch retinal vein occlusion(BRVO). Materials and Methods:A total of 43 eyes of 43 patients who underwent intravitreal injections for macular edema due to BRVO were studied retrospectively.The study group consisted of 17 patients,who underwent intravitreal Ranibizumab(Lucentis®),16 patients who underwent intravitreal Dexamethasone Implants(Ozurdex®)and 10 patients who underwent IVTA.Bestcorrected visual acuity(BCVA),central macular thickness(CMT),subfoveal choroidal thickness(SFCT),intraocular pressure(IOP)and changes in lens status were measured before and after injection at 1st month,3rd month,6th month and 12th month in all three groups. Results:Patients were followed-up at least one year.BCVA increased at all visits in Ranibizumab and Dexamethasone Implant group,whereas significant BCVA increase was only observed at 1st and 6th month during follow-up in IVTA group.CMT was significantly decreased in all three groups(p=0,007,p=0,001,p=0,044).IOP did'nt increase in any patient in Ranibizumab group,but increased in 3 patients(18.8%)in Dexamethasone Implant group and in 3 patients(30%)in IVTA group.No patient had undergone cataract surgery in Ranibizumab group. One patient(6.3%)had undergone cataract surgery in Dexamethasone Implant group and 3 patients(30%)had undergone cataract surgery in IVTA group.SFCT was decreased in first month after the injection in all three groups but there was no significant change in other months. Conclusion:Intravitreal Ranibizumab,Dexamethasone Implant and Triamcinolone can be used effectively in treatment of macular edema due to BRVO.This study shows that intravitreal Ranibizumab injections are more reliable than other groups. Keywords:Branch Retinal Vein Occlusion,Macular Edema,Intravitreal Ranibizumab,Intravitreal Dexamethasone Implant,Intravitreal TriamcinoloneAsetonid

Long-term Results of Ranibizumab, Dexamethasone Implant, and Triamcinolone in Macular Edema due to Branch Retinal Vein Occlusion

Objectives: The present study aims to compare the long-term efficacy and safety results of intravitreal ranibizumab (RAN), dexamethasone intravitreal implant (DEX) and intravitreal triamcinolone acetonide (IVTA) injections in macular edema due to branch retinal vein occlusion (BRVO). Methods: In this retrospective study, one eye each of 43 patients who were treated with intravitreal injections for macular edema secondary to BRVO was recruited into one of the study groups: RAN group (n=17), DEX group (n=16) and IVTA group (n=10). All patients were followed-up for 12 months. Best-corrected visual acuity (BCVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT) and intraocular pressure (IOP) at month 1, 3, 6, and 12 were compared with baseline. Results: The BCVA increased significantly in the RAN and DEX groups at all visits (all p<0.05). BCVA increase in the IVTA group was significant only at month 1 and 6. CMT decreased significantly in all groups at the end of one year of follow-up (p=0.007; p=0.001; p=0.044, respectively). SFCT significantly decreased in all groups at month 1 (all p<0.05). IOP significantly increased in none, 18.8%, 30% of the patients in the RAN, DEX and IVTA groups, respectively. Cataract surgery was performed in none of the patients, 6.3%, and 30% of the patients in the RAN, DEX, and IVTA groups, respectively. Conclusion: BCVA increase was more prominent in both of the RAN and DEX groups than in the IVTA group. DEX may decrease the injection burden; however, ranibizumab may be a safer choice

Comparison of choroidal thickness changes following intravitreal dexamethasone, ranibizumab, and triamcinolone in eyes with retinal vein occlusion

WOS: 000393691000031PubMed: 26847213Purpose: To evaluate short-term choroidal thickness changes following intravitreal dexamethasone implant (DEX), ranibizumab (RAN), and triamcinolone acetonide (TA) in eyes with retinal vein occlusion (RVO) and macular edema (ME). Methods: In this prospective study, 35 eyes of 35 patients with RVO and ME who were treated with intravitreal injections of DEX, RAN, and TA were included. Choroidal thickness was measured using semiautomated segmentation of enhanced depth imaging with optical coherence tomography at fovea and parafoveal areas. Changes in choroidal thickness following treatment were compared statistically. Results: Choroidal thickness decreased following DEX, RAN, and TA treatments (all p>0.05). In the DEX group, at the first month nasal 1,500 mu m (N1(1,500)) and at the third month subfoveal (SF3) and nasal 500 mu m (N3(500)) choroidal thickness revealed a significant reduction compared to RAN and TA groups (all p<0.05). In the TA group, choroidal thickness showed a significant reduction only at nasal 1,500 mu m (N3(1,500)) at the third month (p<0.05). Conclusions: Choroidal thickness was decreased in all 3 groups. The DEX and TA groups showed a significant reduction at some areas. Ranibizumab had the smallest effect on choroidal thickness after 3 months among all groups

Changes in the choroidal thickness in reproductive-aged women with iron-deficiency anemia

yumusak, erhan/0000-0002-9296-8451WOS: 000367527800002PubMed: 26715579Background: The aim of this study was to investigate the potential significance of the central macular thickness (foveal thickness-FT) and choroidal thickness (CT) in the eyes of patients with iron-deficiency anemia, the most common form of the anemia, via enhanced-depth imaging optical coherence tomography (EDI-OCT). We also investigated whether such changes might serve as an early indicator of underlying hematological disease. Methods: This prospective clinical study compared 96 female patients with iron-deficiency anemia and 60 healthy female control subjects. The macular and choroidal thicknesses in the temporal and nasal subfoveal areas were measured using enhanced-depth imaging optical coherence tomography (EDI-OCT) at 500 and 1500 microns and in five different regions (FCT, T-1500, T-500, N-500, and N-1500). Results: The mean ages of the patients and healthy controls were 34.08 +/- 10.39 years and 32.29 +/- 8.28 years, respectively (P = 0.232). There were no significant changes in macular thickness between the groups (225.58 +/- 19.76 vs. 222.45 +/- 13.51, P = 0.2). The choroidal thickness was significantly reduced in the patient group relative to the controls at all measured points (foveal choroidal thickness, P = 0.042; nasal-500 microns, P = 0.033; temporal-500 microns, P = 0.033; and temporal-1500 microns, P = 0.019). At some points, the choroidal thickness findings correlated with the hemoglobin values (temporal-500 microns, r = -0.287, P = 0.001; nasal-500 microns, r = -0.287, P = 0.005; nasal-1500 microns, r = -0.245, P = 0.016; and temporal-1500 microns, r = -0.280, P = 0.06). Conclusions: Patients with iron-deficiency anemia had a significantly reduced choroidal thickness

The Epidemiology of Open Globe Injuries of the Eye

Amaç: 01.01.2014 ile 01.05.2017 tarihleri arasında açık glob yaralanması nedeniyle başvuran 53 hastanın 53 gözünü epidemiyolojik açıdan retrospektif olarak incelemek. Gereç ve Yöntem: Hasta bilgileri hasta dosyaları taranarak kaydedildi. Çıkarılan hasta verileri yaş, cinsiyet, travma türü (keskin/künt), yer ve travmanın şekli ve hangi gözde olduğu şeklindeydi. Başvuru anındaki ve en son andaki görme keskinliği Snellen'in görme keskinliği çizelgesi kullanılarak kaydedildi. Dilate fundus bulgularını da kapsayan biyomikroskobik muayeneler ayrıntılı olarak not edildi. Bulgular: Hastaların 43’ü (%81,1) erkek, 10’u (%18,9) kadındı. Cinsiyet açısından karşılaştırıldığında açık glob travması erkek hastalarda kadın hastalara göre istatistiksel olarak daha yüksekti (p0.001). Hastaların yaşı arttıkça açık glob yaralanması insidansının azaldığı görüldü. Travmaların %54,7’si iş kazası, %22,6’sı ev kazası, %7,5’i trafik kazası, %13,2’si ev ve iş dışında, %1,9’u ise spor yaparken gerçekleşen kazalardı. Sonuç: Açık glob yaralanmalarının tedavi sonuçları hastalar için yüz güldürücü değildir ve bu tip yaralanmaların çoğunluğu önlenebilir sebeplerden meydana gelmektedir. İş güvenliğine verilecek önem ve toplumun bu konudaki farkındalığını arttıracak eğitimler bu tür yaralanmaların oranını azaltabilir.Objective: Fifty-three eyes of 53 patients with open eye injury who admitted Kırıkkale University Faculty of Medicine Department of Ophthalmology between January 1 2014-May 1 2017 were included in this retrospective study in order to evaluate the epidemiological factors. Material and Methods: Patient data were retrieved from patient’s examination files. Patient data included age, gender, type of trauma (sharp/blunt), location and nature of trauma. Visual acuity at the time of presentation and at discharge were recorded using Snellen’s visual acuity chart. Details of slit lamp examination including fundus examination were noted. Results: Of the patients, 43 (81.1%) were male and 10 (18.9%) were female. Men had a higher rate of open globe trauma than women (p0.001). The incidence of eye injury decreased with increasing age. Work-related injuries constituted 54.7%of traumatic injuries. Home accidents constituted 22.6%, traffic accidents constituted 7.5%, outdoor related activities constituted 13.2%, and sports-related injuries constituted 1.9%of all open globe injuries. Conclusion: The consequences of open globe injuries treatment are not good for patients. Most of these injuries are preventable. Prioritizing job security and educational activities that will raise the public's awareness on this issue can reduce the rate of such injuries